Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BBIO 
BridgeBio Pharma Inc (BBIO)
Today’s top pick
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/30/2025: BBIO (3-star) is a STRONG-BUY. BUY since 36 days. Profits (24.94%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 67.22% | Avg. Invested days 30 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.28B USD | Price to earnings Ratio - | 1Y Target Price 53.82 |
Price to earnings Ratio - | 1Y Target Price 53.82 | ||
Volume (30-day avg) 2488491 | Beta 1.07 | 52 Weeks Range 21.62 - 39.47 | Updated Date 04/1/2025 |
52 Weeks Range 21.62 - 39.47 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.88 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -241.44% | Operating Margin (TTM) -3762.9% |
Management Effectiveness
Return on Assets (TTM) -47.83% | Return on Equity (TTM) -1789.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7339803648 | Price to Sales(TTM) 30.09 |
Enterprise Value 7339803648 | Price to Sales(TTM) 30.09 | ||
Enterprise Value to Revenue 34.36 | Enterprise Value to EBITDA -9.4 | Shares Outstanding 190188992 | Shares Floating 139058316 |
Shares Outstanding 190188992 | Shares Floating 139058316 | ||
Percent Insiders 5.48 | Percent Institutions 91.13 |
Analyst Ratings
Rating 4.41 | Target Price 49.43 | Buy 6 | Strong Buy 9 |
Buy 6 | Strong Buy 9 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BridgeBio Pharma Inc
Company Overview
History and Background
BridgeBio Pharma Inc. was founded in 2015. It focuses on developing therapies for genetic diseases and cancers with clear genetic drivers. The company uses an approach of identifying and acquiring promising early-stage programs and advancing them through clinical development.
Core Business Areas
- Genetic Disease Therapeutics: Development and commercialization of therapies for genetic diseases. This includes drugs targeting specific mutations or pathways relevant to the underlying genetic defect.
- Precision Oncology: Development of targeted therapies for cancers driven by specific genetic alterations. This involves identifying patients with specific genetic profiles who are most likely to respond to a particular therapy.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The organizational structure involves various subsidiaries focused on specific therapeutic areas.
Top Products and Market Share
Key Offerings
- Nulibry (fosdenopterin): Nulibry is approved for the treatment of molybdenum cofactor deficiency (MoCD) Type A, a rare and life-threatening genetic disorder. Market share is substantial within its niche due to the limited treatment options. Competitors are limited due to rarity of disease. Revenue in 2023 was 28.3 million USD.
- Truseltiq (infigratinib): Truseltiq is a kinase inhibitor approved for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with FGFR2 fusions or rearrangements. Competitors include other kinase inhibitors like Pemazyre (pemigatinib). BridgeBio receives royalties from this product. No Market share available.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The focus is shifting towards personalized medicine and targeted therapies.
Positioning
BridgeBio Pharma Inc. is positioned as a leader in developing therapies for genetic diseases and precision oncology, focusing on areas with high unmet medical needs.
Total Addressable Market (TAM)
The total addressable market for genetic disease and precision oncology therapies is estimated to be in the billions of dollars. BridgeBio targets specific patient populations within these markets.
Upturn SWOT Analysis
Strengths
- Strong focus on genetic diseases and precision oncology
- Experienced management team
- Diverse pipeline of product candidates
- Strategic partnerships and collaborations
- Proven ability to identify and develop promising therapies
Weaknesses
- Reliance on successful clinical trials and regulatory approvals
- High research and development costs
- Dependence on key personnel
- Commercialization risks
- Limited number of currently approved products
Opportunities
- Expansion into new therapeutic areas
- Acquisition of additional product candidates
- Partnerships with larger pharmaceutical companies
- Advancements in genetic testing and diagnostics
- Growing demand for personalized medicine
Threats
- Competition from other biopharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Adverse clinical trial results
- Pricing pressures
Competitors and Market Share
Key Competitors
- REGN
- VRTX
- BLUE
Competitive Landscape
BridgeBio competes with larger pharmaceutical companies and smaller biotech firms in various therapeutic areas. Its strength lies in its focus on genetic diseases and precision oncology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: BridgeBio's growth has been driven by its expanding pipeline and strategic acquisitions. They have yet to reach consistent profitability.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals of its pipeline candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing key pipeline programs and exploring strategic partnerships.
Summary
BridgeBio Pharma is a company focused on genetic diseases and precision oncology. Their strength is in the targeted approach, but weaknesses come from R&D risk and regulatory hurdles. They have shown revenue growth, but need to achieve profitability. Future growth relies on clinical trials.
Similar Companies
ALNY
Alnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
BLUE
Bluebird bio Inc
BLUE
Bluebird bio Inc
IONS
Ionis Pharmaceuticals Inc
IONS
Ionis Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Investor Relations
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on estimates and may not be precise. This analysis is subject to change based on new information and market conditions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BridgeBio Pharma Inc
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2019-06-27 | Co-Founder, CEO & Director Dr. Neil Kumar Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 725 | Website https://bridgebio.com |
Full time employees 725 | Website https://bridgebio.com | ||
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.